|
1.
|
|
8 p, 334.2 KB |
Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer : Retrospective Testing of Specimens from the EURTAC Trial
/
Benlloch, Susana (Pangaea Biotech) ;
Botero, Maria Luisa (Pangaea Biotech) ;
Beltran-Alamillo, Jordi (Pangaea Biotech) ;
Mayo, Clara (Pangaea Biotech) ;
Giménez-Capitán, Ana (Pangaea Biotech) ;
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Queralt, C (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Klughammer, Barbara (F. Hoffmann-La Roche, Basel) ;
Schlegel, Mariette (F. Hoffmann-La Roche, Basel) ;
Bordogna, Walter (F. Hoffmann-La Roche, Basel) ;
Chen, David (Genentech, South San Francisco, California) ;
Zhang, Guili (Roche Molecular Systems, Pleasanton, California) ;
Kovach, Barbara (Roche Molecular Systems, Pleasanton, California) ;
Shieh, Felice (Roche Molecular Systems, Pleasanton, California) ;
Palma, John F. (Roche Molecular Systems, Pleasanton, California) ;
Wu, Lin (Roche Molecular Systems, Pleasanton, California) ;
Lawrence, H. Jeffrey (Roche Molecular Systems, Pleasanton, California) ;
Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. [...]
2014 -  10.1371/journal.pone.0089518
PloS one, Vol. 9 (february 2014)
|
|
|
2.
|
|
13 p, 2.2 MB |
Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesia, Carles (Institut Català d'Oncologia) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ;
Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ;
Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086
|
|
|
3.
|
|
1 p, 789.3 KB |
Correction : Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesia, Carles (Institut Català d'Oncologia) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ;
Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ;
Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
2019 - 10.18632/oncotarget.26855
Oncotarget, Vol. 10 (april 2019) , p. 2576
|
|
|
4.
|
|
17 p, 2.4 MB |
Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients
/
Ruiz de Porras, V. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bystrup, Sara (Institut Germans Trias i Pujol) ;
Cabrero de las Heras, Sara (Institut Germans Trias i Pujol) ;
Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Palomero, L. (Institut d'Investigació Biomèdica de Bellvitge) ;
Alonso, M. H. (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno, V. (Universitat de Barcelona. Departament de Ciències Clíniques) ;
Queralt, C. (Institut Germans Trias i Pujol) ;
Manzano Mozo, José Luís (Institut Germans Trias i Pujol) ;
Layos, Laura (Institut Germans Trias i Pujol) ;
Bugés, Cristina (Institut Germans Trias i Pujol) ;
Martínez Balibrea, Eva (Institut Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. [...]
2019 - 10.3390/cancers11101540
Cancers, Vol. 11 Núm. 10 (october 2019) , p. 1540
|
|
|
5.
|
|
12 p, 1.4 MB |
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
/
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Karachaliou, Niki (Instituto Oncológico Dr. Rosell, Institut Universitari Quirón-Dexeus) ;
Pilotto, Sara (Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona) ;
Codony-Servat, Jordi (Pangaea Biotech, Laboratory of Molecular Biology) ;
Cai, Xueting (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Li, Xuefei (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Drozdowskyj, Ana (Pivotal, Madrid) ;
Codony Servat, Carles (Pangaea Biotech, Laboratory of Molecular Biology) ;
Yang, Jie (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Hu, Chunping (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine) ;
Cardona Zorrilla, Andrés Felipe (Clinica del Country, Bogotá) ;
Lopez Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Vergnenegre, Alain (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Sanchez, Jose Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Marinis, Filippo de (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Passaro, Antonio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Carcereny, Enric (Service de Pathologie Respiratoire et d'Allergologie, CHU, Limoges France) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Garcia Campelo, Charo (Hospital Universitario de la Princesa (Madrid)) ;
Teixidó, Cristina (Pangaea Biotech, Laboratory of Molecular Biology) ;
Sperduti, Isabella (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodriguez, Sonia (Pangaea Biotech, Laboratory of Molecular Biology) ;
Lavazzi, Chiara (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Verlicchi, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Aguirre, Itziar de (Institut Germans Trias i Pujol) ;
Queralt, C (Institut Germans Trias i Pujol) ;
Wei, Jia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Estrada-Tejedor, Roger (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Puig de la Bellacasa, Raimon (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol) ;
Jacobson, Kirstine (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Ditzel, Henrik J. (WV Clinical and Translational Science Institute, Morgantown, WV, USA) ;
Santarpia, Mariacarmela (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Viteri, Santiago (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina, Miguel Angel (Pangaea Biotech, Laboratory of Molecular Biology) ;
Zhou, Caicun (Shangai Pulmonary Hospital, Tongji University School of Medicine, Shangai) ;
Cao, Peng (Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China) ;
Ma, Patrick C. (WVU Cancer Institute, West Virginia University, Morgantown, WV, USA) ;
Bivona, Trever (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Background: The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non- small cell lung cancer (NSCLC) is limited by adaptive activation of cell survival signals. [...]
2017
Journal of the National Cancer Institute, Vol. 109 (september 2017) , p. 1-12
|
|
|
6.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
